• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Establishment Labs Holdings Inc.

    2/28/25 4:04:31 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    S-8 1 estas-82025_.htm S-8 Document

    Registration No. 333-
        
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S‑8
    REGISTRATION STATEMENT
    UNDER
     THE SECURITIES ACT OF 1933
    Establishment Labs Holdings Inc.
    (Exact name of Registrant as specified in its charter)
    British Virgin IslandsNot applicable
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification Number)
    Building B23 and 25
    Coyol Free Zone
    Alajuela
    Costa Rica
    (Address of principal executive offices including zip code)
    2018 EQUITY INCENTIVE PLAN
    2018 EMPLOYEE SHARE PURCHASE PLAN
    (Full title of the plans)
    Rajbir S. Denhoy
    Motiva USA LLC
    16192 Coastal Highway
    Lewes, DE 19958
    +506 2434 2400
    (Name, address, and telephone number, including area code, of agent for service)
    Copy to:
    Shelly A. Heyduk
    O’Melveny & Myers LLP
    610 Newport Center Drive, 17th Floor
    Newport Beach, CA 92660
    (949) 823-6900

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ý
    Accelerated filer ¨
    Non-accelerated filer ¨
    Smaller reporting company ¨
    Emerging growth company ¨
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨



     PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.    Incorporation of Documents by Reference.
        Establishment Labs Holdings Inc. (the “Registrant”) hereby incorporates by reference into this Registration Statement the following documents and information heretofore filed with the Securities and Exchange Commission (the “Commission”):
    (1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025 pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (File No. 001-38593); and
    (2)The description of the Registrant’s Common Shares contained in the Registrant’s Registration Statement on Form S-1 (File No. 333-225791) initially filed with the Commission on June 21, 2018, as modified by the description of the Registrant’s Common Shares contained in Exhibit 4.8 of the Registrant’s Annual Report for the year ended December 31, 2019, filed with the Commission on March 16, 2020, and any other amendment or report filed for the purpose of updating such description.
        All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    Item 4.    Description of Securities.
    Not applicable.
    Item 5.    Interests of Named Experts and Counsel.
    Not applicable.
    Item 6.    Indemnification of Directors and Officers.



    The BVI Business Companies Act, 2004, as amended, or the BVI Act, and the Registrant’s amended and restated memorandum and articles of association provide for the indemnification of its directors against all losses or liabilities incurred or sustained by him or her as a director of the Registrant in defending any proceedings, whether civil or criminal provided that this indemnity only applies if he or she acted honestly and in good faith with a view to the Registrant’s best interests and, with respect to any criminal action, he or she must have had no reasonable cause to believe his or her conduct was unlawful.
    In addition to the indemnification required in the Registrant’s amended and restated memorandum and articles of association, the Registrant has entered into indemnification agreements with each of its current directors and officers. These agreements provide indemnification for certain expenses and liabilities incurred in connection with any action, suit, proceeding, or alternative dispute resolution mechanism, or hearing, inquiry, or investigation that may lead to the foregoing, to which they are a party, or are threatened to be made a party, by reason of the fact that they are or were a director, officer, employee, agent, or fiduciary of the Registrant, or any of its subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent, or fiduciary, or by reason of the fact that they were serving at its request as a director, officer, employee, agent, or fiduciary of another entity. In the case of an action or proceeding by, or in the right of, the Registrant or any of its subsidiaries, no indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. The Registrant believes that these article provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. The Registrant also maintains directors’ and officers’ liability insurance.
    The limitation of liability and indemnification provisions in the Registrant’s amended and restated memorandum and articles of association may discourage shareholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit the Registrant or its shareholders. A shareholder’s investment may be harmed to the extent the Registrant pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
    See also the undertakings set out in response to Item 9 herein.
    Item 7.    Exemption from Registration Claimed.
    Not applicable.
    Item 8.    Exhibits.
        See Exhibit Index immediately preceding the Signature Page.
    Item 9.    Undertakings.
    A.    The undersigned Registrant hereby undertakes:

    (1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
     
    (i)    to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)    to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and



    price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii)    to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
     
    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
     
    (2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    B.    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    C.    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant’s directors, officers and controlling persons pursuant to applicable law, the Registrant’s Amended and Restated Memorandum and Articles of Association or indemnification agreements, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, the Registrant will, unless in the opinion of the Registrant’s counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by the Registrant is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    INDEX TO EXHIBITS
    Exhibit NumberDescription
    4.1(1)
    2018 Equity Incentive Plan and related form agreements.
    4.2(2)
    2018 Employee Share Purchase Plan and related form agreements.
    5.1
    Opinion of Conyers Dill & Pearman.
    23.1
    Consent of Independent Registered Public Accounting Firm.
    23.2
    Consent of Conyers Dill & Pearman (see Exhibit 5.1).
    24.1
    Power of Attorney (included on the signature page hereto).
    107
    Filing Fee Table.
    __________

    (1)Incorporated by reference to Exhibit 10.3 filed with Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-225791), filed with the Commission on July 9, 2018.
    (2)Incorporated by reference to Exhibit 10.4 filed with Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-225791), filed with the Commission on July 9, 2018.





    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San José, Costa Rica, on February 28, 2025.

    ESTABLISHMENT LABS HOLDINGS
     By:
    /s/ Juan José Chacón Quirós
    Juan José Chacón Quirós
    Chief Executive Officer and Director





















        


    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Juan José Chacón Quirós and Rajbir S. Denhoy, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her in his or her name, place and stead, in any and all capacities to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
    SignatureTitleDate
    /s/ Juan José Chacón Quirós
    Chief Executive Officer and Director (Principal Executive Officer)February 28, 2025
    Juan José Chacón Quirós
    /s/ Rajbir S. Denhoy
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    (Authorized Representative in the United States)
    February 28, 2025
    Rajbir S. Denhoy
    /s/ Nicholas Lewin
    Chairman of the Board of DirectorsFebruary 28, 2025
    Nicholas Lewin
    /s/ Ann CustinDirectorFebruary 28, 2025
    Ann Custin
    /s/ Leslie GillinDirectorFebruary 28, 2025
    Leslie Gillin
    /s/ Edward Schutter
    DirectorFebruary 28, 2025
    Edward Schutter
    /s/ Bryan SlotkinDirectorFebruary 28, 2025
    Bryan Slotkin


    Get the next $ESTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    10/13/2022$70.00Buy
    Mizuho
    8/24/2022$107.00Buy
    B. Riley Securities
    11/10/2021$88.00 → $90.00Overweight
    Stephens & Co.
    More analyst ratings

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lewin Nicholas Sheridan bought $54,073 worth of shares (2,000 units at $27.04), increasing direct ownership by 0.19% to 1,064,888 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      12/15/23 7:59:37 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $110,000 worth of shares (5,000 units at $22.00) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/21/23 8:00:55 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/20/23 8:00:42 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and CCO Mansbach Samuel Ross was granted 7,952 shares, increasing direct ownership by 109% to 15,238 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:50:37 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Chief Financial Officer Denhoy Raj was granted 11,200 shares, increasing direct ownership by 92% to 23,348 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:49:52 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Int Chief Executive Officer Caldini Filippo was granted 17,231 shares, increasing direct ownership by 207% to 25,539 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      4/4/25 4:48:39 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Establishment Labs Holdings Inc.

      10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/9/25 4:01:46 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

      DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:05:26 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/7/25 4:04:12 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces CEO Transition

      Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

      1/13/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat

      5/1/24 8:30:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 12:54:20 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 9:03:38 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

      SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      2/14/24 4:51:40 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Financials

    Live finance-specific insights

    See more
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter net loss from operations of $18.7 million, a 15% reduction compared to a net loss of $22.1 million in the year-ago period. F

      2/26/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Establishment Labs

      Needham initiated coverage of Establishment Labs with a rating of Hold

      4/14/25 7:48:56 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs downgraded by Citigroup with a new price target

      Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00

      5/22/24 7:26:41 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Establishment Labs with a new price target

      JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00

      8/31/23 7:13:36 AM ET
      $ESTA
      Industrial Specialties
      Health Care